Lin, M.-H.; Yang, H.-Y.; Yen, C.-L.; Wu, C.-Y.; Jenq, C.-C.; Kuo, G.; Peng, W.-S.; Liu, J.-R.; Tian, Y.-C.; Yang, C.-W.;
et al. Pioglitazone Is Associated with Lower Major Adverse Cardiovascular and Cerebrovascular Events than DPP4-Inhibitors in Diabetic Patients with End-Stage Renal Disease: A Taiwan Nationwide Cohort Study, 2006–2016. J. Clin. Med. 2020, 9, 3578.
https://doi.org/10.3390/jcm9113578
AMA Style
Lin M-H, Yang H-Y, Yen C-L, Wu C-Y, Jenq C-C, Kuo G, Peng W-S, Liu J-R, Tian Y-C, Yang C-W,
et al. Pioglitazone Is Associated with Lower Major Adverse Cardiovascular and Cerebrovascular Events than DPP4-Inhibitors in Diabetic Patients with End-Stage Renal Disease: A Taiwan Nationwide Cohort Study, 2006–2016. Journal of Clinical Medicine. 2020; 9(11):3578.
https://doi.org/10.3390/jcm9113578
Chicago/Turabian Style
Lin, Min-Hao, Huang-Yu Yang, Chieh-Li Yen, Chao-Yi Wu, Chang-Chyi Jenq, George Kuo, Wei-Sheng Peng, Jia-Rou Liu, Ya-Chung Tian, Chih-Wei Yang,
and et al. 2020. "Pioglitazone Is Associated with Lower Major Adverse Cardiovascular and Cerebrovascular Events than DPP4-Inhibitors in Diabetic Patients with End-Stage Renal Disease: A Taiwan Nationwide Cohort Study, 2006–2016" Journal of Clinical Medicine 9, no. 11: 3578.
https://doi.org/10.3390/jcm9113578
APA Style
Lin, M.-H., Yang, H.-Y., Yen, C.-L., Wu, C.-Y., Jenq, C.-C., Kuo, G., Peng, W.-S., Liu, J.-R., Tian, Y.-C., Yang, C.-W., Anderson, G. F., & See, L.-C.
(2020). Pioglitazone Is Associated with Lower Major Adverse Cardiovascular and Cerebrovascular Events than DPP4-Inhibitors in Diabetic Patients with End-Stage Renal Disease: A Taiwan Nationwide Cohort Study, 2006–2016. Journal of Clinical Medicine, 9(11), 3578.
https://doi.org/10.3390/jcm9113578
